News & Events zu Metagenomi Therapeutics Inc (MGX)MGXMetagenomi Therapeutics Inc

Metagenomi Therapeutics Advances MGX-001 Program to Clinical Trials

"During the second quarter, we continued to execute against our strategic priorities while advancing toward our planned regulatory submissions for our MGX-001 program in hemophilia A later this year," said Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics. "As we prepare to enter the clinic, we are engaging with leading hemophilia investigators and key opinion leaders to establish a strong foundation for our first-in-human study. We believe our differentiated genome editing platform positions us to pursue durable genetic medicines, and we remain focused on disciplined execution as we move toward our upcoming regulatory and clinical milestones."

Metagenomi Q1 Revenue $1.25M, Below Consensus $5.92M

Reports Q1 revenue $1.25M, consensus $5.92M. "We remain diligently focused on advancing our core genome-editing technologies, led by our MGX-001 program for hemophilia A, which remains on track for regulatory submission in the fourth quarter of this year and first-in-human studies in 2027," said Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics. "The promise of our novel technology, most recently highlighted by a Nature publication, in addition to the encouraging preclinical data and continued IND-enabling execution, gives us confidence in our goal to provide patients an option for one-time, curative treatments, beginning with hemophilia A."

Metagenomi Publishes MG119-28 Research Findings

Metagenomi Therapeutics announced a publication in Nature Structural & Molecular Biology highlighting the discovery and detailed characterization of MG119-28, a compact CRISPR nuclease with superior editing efficiency relative to previously identified compact nucleases. The publication, titled "Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency" highlights the potential of MG119-28 to overcome low editing efficiency in mammalian systems of previously identified compact nucleases from the Cas12f class. "The publication demonstrates that the enhanced editing performance is due to superior structural stability of the protein and inherently more stable guide RNA which enables faster DNA cleavage activity. The structural and mechanistic insights enabled engineering of MG119-28 to further improve activity across multiple target genes," the company said.